Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma

Lung adenocarcinoma or non-small cell lung cancer (NSCLC) represents one of the most diagnosed cancers worldwide. Anaplastic lymphoma kinase (ALK) mutation, a tyrosine kinase and ALK fusion or rearrangement oncogene, has been found rarely in patients with NSCLC. Newer treatment modalities with diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashish, Sethi, Rodriguez, Robin R, Sethi, Purva, Yu, Fang, Raj, Moses
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633320/
https://www.ncbi.nlm.nih.gov/pubmed/36348885
http://dx.doi.org/10.7759/cureus.29922
_version_ 1784824239603318784
author Ashish, Sethi
Rodriguez, Robin R
Sethi, Purva
Yu, Fang
Raj, Moses
author_facet Ashish, Sethi
Rodriguez, Robin R
Sethi, Purva
Yu, Fang
Raj, Moses
author_sort Ashish, Sethi
collection PubMed
description Lung adenocarcinoma or non-small cell lung cancer (NSCLC) represents one of the most diagnosed cancers worldwide. Anaplastic lymphoma kinase (ALK) mutation, a tyrosine kinase and ALK fusion or rearrangement oncogene, has been found rarely in patients with NSCLC. Newer treatment modalities with different ALK inhibitors in targetable specific ALK mutations have recently made great strides in the management of NSCLC patients. We present a case of NSCLC harboring ALK mutation with primary cutaneous marginal zone B-cell lymphoma (PCMZL) treated with adjuvant chemotherapy with pemetrexed and cisplatin, and ALK-echinoderm microtubule-associated protein-like 4 (EML4)-targeting treatment alectinib.
format Online
Article
Text
id pubmed-9633320
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-96333202022-11-07 Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma Ashish, Sethi Rodriguez, Robin R Sethi, Purva Yu, Fang Raj, Moses Cureus Internal Medicine Lung adenocarcinoma or non-small cell lung cancer (NSCLC) represents one of the most diagnosed cancers worldwide. Anaplastic lymphoma kinase (ALK) mutation, a tyrosine kinase and ALK fusion or rearrangement oncogene, has been found rarely in patients with NSCLC. Newer treatment modalities with different ALK inhibitors in targetable specific ALK mutations have recently made great strides in the management of NSCLC patients. We present a case of NSCLC harboring ALK mutation with primary cutaneous marginal zone B-cell lymphoma (PCMZL) treated with adjuvant chemotherapy with pemetrexed and cisplatin, and ALK-echinoderm microtubule-associated protein-like 4 (EML4)-targeting treatment alectinib. Cureus 2022-10-04 /pmc/articles/PMC9633320/ /pubmed/36348885 http://dx.doi.org/10.7759/cureus.29922 Text en Copyright © 2022, Ashish et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Ashish, Sethi
Rodriguez, Robin R
Sethi, Purva
Yu, Fang
Raj, Moses
Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma
title Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma
title_full Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma
title_fullStr Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma
title_full_unstemmed Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma
title_short Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma
title_sort anaplastic lymphoma kinase (alk) mutation-targeting treatment with alectinib in lung adenocarcinoma and primary cutaneous marginal zone b-cell lymphoma
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633320/
https://www.ncbi.nlm.nih.gov/pubmed/36348885
http://dx.doi.org/10.7759/cureus.29922
work_keys_str_mv AT ashishsethi anaplasticlymphomakinasealkmutationtargetingtreatmentwithalectinibinlungadenocarcinomaandprimarycutaneousmarginalzonebcelllymphoma
AT rodriguezrobinr anaplasticlymphomakinasealkmutationtargetingtreatmentwithalectinibinlungadenocarcinomaandprimarycutaneousmarginalzonebcelllymphoma
AT sethipurva anaplasticlymphomakinasealkmutationtargetingtreatmentwithalectinibinlungadenocarcinomaandprimarycutaneousmarginalzonebcelllymphoma
AT yufang anaplasticlymphomakinasealkmutationtargetingtreatmentwithalectinibinlungadenocarcinomaandprimarycutaneousmarginalzonebcelllymphoma
AT rajmoses anaplasticlymphomakinasealkmutationtargetingtreatmentwithalectinibinlungadenocarcinomaandprimarycutaneousmarginalzonebcelllymphoma

Ejemplares similares